Refractory metastatic triple-negative breast cancer (TNBC) is a type of breast cancer that tests negative for progesterone receptors, estrogen receptors, and excess HER2 protein. Sacituzumab Govitecan-hziy is an antibody-drug used for the treatment of triple-negative breast cancer. This study aims to evaluate the outcomes of sacituzumab govitecan-hziy in patients with refractory metastatic TNBC.

This multicenter, phase 1/2 single-group trial included a total of 108 patients with triple-negative breast cancer. The patients received sacituzumab govitecan-hziy at a dose of 10 mg per kg body weight. The primary outcomes of the study were the overall safety of the treatment, progression-free survival, and overall survival.

Out of 108 patients who received sacituzumab govitecan-hziy, 4 patients (3.7%) died during the treatment, and 3 (2.8%) discontinued the treatment due to adverse events. The most common treatment-related adverse events (grade 3 or 4), which occurred in more than 10% of patients, were anemia and neutropenia. The response rate of the treatment was 33.3%, with the median duration of response being 7.7 months. The progression-free and overall survivals were 5.5 months and 13.0 months, respectively.

The research concluded that sacituzumab govitecan-hziy was associated with positive outcomes in patients with advanced refractory metastatic triple-negative breast cancer.